Abstract:Background: Glycated albumin (GA) levels have been considered as a promising biomarker for estimating glycemic control during pregnancy, but the relationship between GA levels and the incidence of adverse pregnancy outcomes in women with gestational diabetes mellitus (GDM) remains unclear. Our study aimed to investigate the relationship between GA levels during the third trimester and 13 different adverse pregnancy-related outcomes among women with GDM in China. Methods: We retrospectively extracted clinical data from the medical records of 819 pregnant women with GDM who underwent prenatal examinations and child delivery at the Affiliated Hospital of Qingdao University between January 2022 and October 2022. The cohort was divided into GA-high (GA-H) and GA-low (GA-L) groups based on the median GA level of 10.6%. Then, the incidence rates of 13 specific adverse pregnancy outcomes were compared between the two groups. Furthermore, we estimated the mean GA levels in pregnant GDM women with or without specific adverse outcomes. Multivariate logistic regression analysis was performed to assess whether the GA levels (high or low) were independent risk factors for specific adverse outcomes in pregnant women with GDM. Receiver operating characteristic (ROC) curve analysis was performed to assess the predictive value of GA levels for the adverse pregnant outcomes in women with GDM. E-value for sensitivity analysis was performed to assess the robustness of the findings to unmeasured confoundings. Results: We included 819 pregnant women with GDM, whose average age was 33.09 ± 4.47 years, average pre-pregnancy BMI was 23.51 ± 3.67 kg/m2, and the average gestational week in which GDM diagnosed was 24.80 ± 1.79 weeks. The analysis showed that 80.71% (661/819) pregnant women with GDM were associated with adverse pregnancy-related outcomes. Pregnant women in the GA-L group showed higher incidence of the premature rupture of membranes (PROM), whereas those in the GA-H group showed higher incidence of neonatal hypoglycemia. The GA levels showed acceptable clinical performance for predicting neonatal hypoglycemia with an area under the ROC curve (AUC) value of 0.700 (P = 0.010), sensitivity of 71.4%, and specificity of 70.2%. The optimal cut off value for GA was 11.55%. Conclusions: This study demonstrated that GA levels were significantly associated with specific adverse pregnancy outcomes, especially PROM and neonatal hypoglycemia. Furthermore, GA levels in the third trimester showed acceptable clinical performance for predicting neonatal hypoglycemia among pregnant women with GDM. In the future, the potential role of GA as a predictor of adverse pregnancy outcomes need to be further confirmed and explored in GDM women.

Significance of glycosylated hemoglobin A1c and glycated albumin for the diagnosis of gestational diabetes mellitus

The Influence of HbA1c and Gestational Weight Gain on Pregnancy Outcomes in Pregnant Women with Gestational Diabetes Mellitus

The diagnostic accuracy of HbA1c in detecting gestational diabetes mellitus among Chinese pregnant individuals

Clinical Significance of Glycosylated Hemoglobin Test in Gestational Diabetes Mellitus

The Utility of HbA1c for Screening Gestational Diabetes Mellitus and Its Relationship with Adverse Pregnancy Outcomes

Circulating glycated albumin levels and gestational diabetes mellitus

The Diagnosis Value Of Blood Glucose Combined Glycosylated Hemoglobin In Gestational Diabetes

Glycosylated hemoglobin level in diagnosis and management of gestational diabetes mellitus

Association between glycemic control and birthweight with glycated albumin in Chinese women with gestational diabetes mellitus.

[Combined utility of hemoglobin A1c and glycated albumin in diabetic screening].

Assessment of enzymatic method for glycated albumin and its correlation research with the diagnosis of diabetes mellitus

Influence of Insulin Sensitivity and Secretion on Glycated Albumin and Hemoglobin A1c in Pregnant Women with Gestational Diabetes Mellitus

Glycated Albumin in Screening the Abnormal Glucose Metabolism in Postpartum Women with Previous Gestational Diabetes Mellitus

Clinical Significance of Glycosylated Hemoglobin in Screening Gestational Diabetes Mellitus

Investigation of Glucohemoglobin in Gestational Diabetes Mellitus

Application of Glycated Hemoglobin in the Perinatal Period.

The Clinical Effects of Glycated Hemoglobin, Fasting Blood Glucose and Serum C-peptide Combined Screening for Gestational Diabetes Screening and Its Clinical Significance

The Diagnostic Value of Glycosylated Hemoglobin for Gestational Diabetes Mellitus in Asian Populations: A Systematic Review and Meta‐analysis

Glycated albumin levels in the third trimester of women with gestational diabetes mellitus are associated with adverse pregnancy-related outcomes

Glycated albumin is superior to glycated hemoglobin for glycemic control assessment at an early stage of diabetes treatment: A multicenter, prospective study

Combined Assessment of Glycated Albumin and Fasting Plasma Glucose Improves the Detection of Diabetes in Chinese Subjects